'Highly commended antibody supplier' in Citeab Awards 2018

Proteintech recognized as a 'Highly commended antibody supplier' in Citeab 2018 awards.


Proteintech has been highly commended by Citeab as the Antibody supplier to watch in 2018’  in this years’ Cawards. 

The Citeab awards recognize and reward the best suppliers of research reagents worldwide.

‘Antibody supplier to watch in 2018’ category

'Antibody supplier to watch in 2018' is an exciting award that looks at growth trajectories, recognizing the company with the largest percentage increase in citations based on data gathered between January 2017 and December 2017. 

Back in 2016 Proteintech also received recognition for their exciting validation initiative.

Proteintech was awarded the prize for the 'most exciting antibody validation initiative' in the 2016 CiteAb antibody awards. The award recognized Proteintech to have the best antibody validation initiative in the industry and was judged by F1000 Research.

Proteintech's antibody validation initiative

The award-winning solution: siRNA Knockdown Validation

In 2014 Proteintech became the first company to implement  siRNA knockdown validation, one of the most trusted validation processes for antibody specificity. The validation process involves using small interfering RNA to knock down gene expression in each new antibody product — assessing whether the signal subsides with the expression of the target gene. Proteintech have made it their goal to lead the way in raising validation standards and aim to have as much of its portfolio verified by this advanced technique as soon as possible.

Read more about Proteintech's siRNA Knockdown validation initiative   here.


About CiteAb 

CiteAb is the largest citation-ranked antibody search engine allowing researchers to find antibodies which have been cited in peer-reviewed publications. The annual CiteAb awards recognize and celebrate the very best suppliers and individuals in the antibody industry. 

Read more about the award   here.

Company News

Posted:
1 February, 2018

Share:


Back
to top